About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany. Address: An der Goldgrube 12, Mainz, Germany, 55131
BioNTech SE News and around…
Latest news about BioNTech SE (BNTX) common stock and company :
Dr. Ben Weston, Milwaukee COVID-19 Emergency Operations Center Medical Director, talks about the process of approving the COVID-19 vaccine for children and the global fight against COVID-19.
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Novavax may be on the verge of good news from U.K. regulators. NVAX stock is reacting well to the impending news. The post NVAX Stock Soars 6% as Novavax Reaches Key Vaccine Milestone appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar
These are no-brainer stocks to buy before the year is over.
In positive news for parents, a U.S. Food and Drug Administration advisory committee voted 17-0 in favor of vaccinating children aged 5 to 11 with the shots developed by Pfizer and BioNTech. agreeing that the benefits outweigh the risks in that age group.
Higher sales of Pfizer's (PFE) key brands, Ibrance, Eliquis and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the third quarter.
The FDA's Vaccines and Related Biological Products Advisory Committeevoted 17-0 favorPfizer Inc(NYSE: PFE) ...
Mainz, Germany, October 27, 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter on Tuesday, November 9th, 2021. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. ET (2.00 p.m. CET) to report its financial results and provide a corporate update for the third quarter 2021. The slide presentation and audio of the webcast wi
After a stellar 2020 run, the stock is 60% off its highs.
A panel advising the FDA recommended the Pfizer-BioNTech vaccine for kids. The decision now rests with the agency.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 17 to 0, with 1 abstention, to recommend the FDA grant Emergency Use Authorization (EUA) for the companies’ COVID-19 vaccine in children 5 to
BioNTech SE Sponsored ADR (BNTX) closed at $292.39 in the latest trading session, marking a -0.86% move from the prior day.
Vaccine stocks popped Tuesday after an expert panel recommended the FDA authorize Pfizer's Covid vaccine for children.
'Most children will not have symptoms severe enough that they need to miss school,' said Dr. Nipunie Rajapakse, a pediatric infectious disease specialist with the Mayo Clinic Children’s Center.
BioNTech SE(NASDAQ:BNTX) said it hadsigned a Memorandum of Understandingwith the Rwandan government and ...
A group of scientists who advise the Food and Drug Administration said the benefits of BioNTech and Pfizer's COVID-19 vaccine outweigh the risks for children between the ages of 5 and 11.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors seeking big payouts should consider these seven high-yield stocks from various sectors. They range from pharmaceuticals to REITs. The post 7 High-Yield Stock Gems for Income-Obsessed Investors appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar
An FDA panel convened Tuesday to discuss Pfizer and BioNTech's Covid vaccine in children — leading the vaccine stocks to diverge.
The global tally of confirmed cases of the coronavirus-borne illness COVID-19 topped 244 million on Tuesday, as a U.S. Food and Drug Administration advisory committee gathered to discuss and vote on whether to recommend the Pfizer/BioNTech vaccine for children aged 5 to 11.
An expert panel on Tuesday voted overwhelmingly to recommend the U.S. Food and Drug Administration authorize the Pfizer Inc and BioNTech SE COVID-19 vaccine for children ages 5 to 11, saying the benefits of the shot outweigh the risks. An authorization for that age group would be would be an important regulatory step toward reaching about 28 million children for inoculation, most of them back in school for in-person learning. The FDA is not obligated to follow the advice of its outside experts, but usually does.
Shares of Moderna Inc. gained 2.2% in premarket trading on Tuesday after the company said it signed a deal to supply the African Union with up to 110 million doses of its COVID-19 vaccine. The first 15 million doses are set to be delivered before the end of this year; the next 35 million in the first quarter of 2022, and up to 60 million in the second quarter of next year. Moderna also said it is developing a plan to allow fill doses of its vaccine in Africa in 2023 and it plans to build a mRNA
Shares of BioNTech SE gained 0.7% in premarket trading on Tuesday after the company said it plans to start building a manufacturing facility for its mRNA vaccines in the African Union in 2022. Once completed, the site is expected to have the capacity to produce several hundreds of millions of doses of BioNTech's vaccines, including the ability to produce the products used to make 50 million COVID-19 vaccine doses per year. BioNTech said it will initially staff and run the facility, but it plans
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Sells Royalties Due ...
Vietnam will begin inoculating children against COVID-19 with the Pfizer-BioNTech vaccine from next month, the health ministry said on Tuesday, as the Southeast Asian country begins reopening its schools following months of lockdown. Children aged 16 and 17 will be offered the shot with parental consent, initially "in the areas that had been under movement restrictions and densely populated areas where the infection risks are high," the ministry said in a statement. Vietnam has recorded over 892,000 COVID-19 infections and 21,700 deaths, the majority in the past few months.
BioNTech signs Memorandum of Understanding with Rwandan Government and the Institut Pasteur de Dakar. Construction of the first mRNA manufacturing facility in Africa is planned to be initiated in mid-2022First manufacturing facility will become a node in a decentralized and robust African end-to-end manufacturing network Development and implementation of a scalable regional manufacturing network to enable an annual manufacturing capacity of several hundreds of million mRNA vaccine doses MAINZ, G
The U.S. Food and Drug Administration is considering authorizing a COVID-19 vaccine for children aged 5 to 11. The vaccine from Pfizer Inc and BioNTech SE has been available in the United States to kids aged 12 to 15 since May. The FDA will consider the recommendation of a committee of outside advisers after that panel meets on Tuesday, and is likely to authorize the vaccine within days.
An expert panel will weigh authorization of Pfizer Inc and BioNTech's COVID-19 vaccine for children aged 5 to 11 on Tuesday as it prepares to vote on a recommendation for the U.S. Food and Drug Administration. The panel's vote is an important regulatory step in getting the vaccine into the arms of millions of children in the United States where schools are largely open for in-person learning. The FDA need not follow the advice of its outside experts, but usually does.
The Vaccines and Related Biological Products Advisory Committee will review data and recommend whether the FDA should authorize use.
The FDA's decision to allow mix-and-match boosters shakes up the COVID-19 vaccine market.